New Hope for MASLD: Heart Drugs Show Promise in Reducing Liver Fat
A groundbreaking study published in Pharmacological Research has revealed promising results for treating metabolic dysfunction-associated steatotic liver disease (MASLD), affecting nearly 40% of adults worldwide. The study found that a combination of two commonly used heart drugs, pemafibrate and telmisartan, can effectively reduce liver fat buildup in animal models of the animal kingdom.
MASLD, previously known as non-alcoholic fatty liver disease, is strongly linked to cardiovascular disease and often associated with overweight or obesity. Left untreated, it can progress to more severe liver diseases like cirrhosis and liver cancer. Currently, few drugs are available to treat the early stages of MASLD, making this discovery significant.
The study found that the combination of pemafibrate and telmisartan was as effective as each drug alone in reducing liver fat buildup in animal models. This suggests that these drugs may be a promising treatment for MASLD if further research confirms their findings. While weight loss is one of the most effective non-pharmacological treatments for MASLD, with even a 3-5% reduction in bodyweight showing benefits, this new approach offers hope for those struggling with the condition.
The combination of pemafibrate and telmisartan has shown promising results in treating MASLD in animal models. If further research confirms these findings, it could provide a new therapeutic option for the millions of people affected by this common liver disease. However, more studies are needed to determine the safety and efficacy of this approach in humans.
